Swedish Tredje AP-Fonden has acquired 5.9 % of the CellaVision shares and is now the fifth largest owner of CellaVision.
"We welcome Tredje AP-fonden as a new institutional owner of CellaVision. We are pleased to broaden our institutional investor base, which was one of the goals when listing the company at NASDAQ OMX", comments Yvonne Mårtensson, CEO of CellaVision.
The five major shareholders of CellaVision are: Industrifonden (15 %), Metallica (11,6 %), Christer Fåhraeus (10,1 %), Life Equity Sweden KB (6,8 %) and Tredje AP-fonden (5,9 %).
Trading in CellaVision shares was moved from the marketplace NASDAQ OMX First North Premier ("First North") to NASDAQ OMX Stockholm, Small Cap on May 31 earlier this year.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: firstname.lastname@example.org
CellaVision AB (publ) develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health care. These analyses often constitute critical reference data for fast and correct diagnosis of illnesses. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in the US, Canada and Japan. For more information, please visit www.cellavision.com.
CellaVision is listed on Nasdaq OMX Stockholm, Small Cap.